Deutsche Bank reiterates Buy on Gilead Sciences stock, $155 target

TL;DR

Deutsche Bank initiates Atai Life Sciences stock at buy on psychedelic therapy potential Deutsche Bank cuts Boliden to “hold” after Garpenberg mine rock fall In a note to clients, analysts highlighted the company’s position in the emerging field of psychedelic medicine for mental health. “Recently, several psychedelic companies have emerged as bona fide drug developers, attracting attention from healthcare and biotech investors who usually invest in conventional therapeutics,” they wrote. “We count ATAI among these trailblazers and believe it will become a leader in the nascent field of psychedelic medicine for mental health conditions.” The firm cited AtaiBeckley’s lead programs, BPL-003 and VLS-01, which are being developed for treatment-resistant depression, an area with high unmet need.